Cargando…
The effect of COVID-19 on patients recieving omalizumab treatment
BACKGROUND AND AIM: Although exposure during drug administration and susceptibility to coronavirus disease-19 (COVID-19) infection secondary to immunomodulatory effects constitute potential risks for patients with chronic spontaneous urticaria (CSU) or asthma on omalizumab (OMZ), there is a risk of...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Masson SAS.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812821/ https://www.ncbi.nlm.nih.gov/pubmed/36624750 http://dx.doi.org/10.1016/j.reval.2023.103281 |